MAZE

Maze Therapeutics Stock Analysis

AI Rating

Low
  • Quality3/10
  • Growth↓ 2/10
  • Value↓ 0/10
Maze Therapeutics sales and earnings growth
MAZE Growth
Fair
  • Revenue Y/Y↓ -89.48%
  • EPS Y/Y↑ 67.15%
  • FCF Y/Y↓ -277.74%
Maze Therapeutics gross and profit margin trends
MAZE Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -612.70%
  • ROIC 5Y↓ 0.00%
Maze Therapeutics net debt vs free cash flow
MAZE Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -140.5

Maze Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks